Ver­sant-backed Chi­nook gets a $65M launch round for its dis­cov­ery quest in a resur­gent kid­ney field

Ver­sant is once again step­ping off the beat­en track in biotech to see if they can blaze a trail of their own in a field that has looked too thorny to many in­vestors for years.

The ven­ture group and their part­ners at Ap­ple Tree are bring­ing their lat­est cre­ation out of stealth mode to­day. Born in Ver­sant’s In­cep­tion Sci­ences’ Chi­nook Ther­a­peu­tics is bet­ting that its pre­clin­i­cal take on kid­ney dis­ease can get an ear­ly lead among the com­pa­nies start­ing up in the field.

Head­ed by Er­ic Dob­meier, who left his post as COO of Seat­tle Ge­net­ics to take up the life of a biotech en­tre­pre­neur, Chi­nook is pur­su­ing a pipeline of pre­clin­i­cal pro­grams born in the be­lief that a bet­ter un­der­stand­ing of bi­ol­o­gy, new tech tools and a sup­port­ive FDA of­fer­ing ac­cel­er­at­ed path­ways is all a new recipe for suc­cess in the pur­suit of pre­ci­sion med­i­cines fo­cused on unique pa­tient pop­u­la­tions.

We don’t know what these drugs are, or specif­i­cal­ly what they are tar­get­ing, yet. But Ver­sant and the Chi­nook team be­lieve they will be in the clin­ic in 2021 when it can say a lot more.

For now, they’re hap­py to stay fo­cused on a resur­gent field lit­tered with the corpses of failed drugs.

Jer­el Davis Ver­sant

“It re­minds me of NASH and liv­er dis­ease 4-plus years ago,” says Ver­sant man­ag­ing di­rec­tor Jer­el Davis. Now phar­ma has be­gun set­ting up its own groups to tack­le the field, and he wants in on the ground floor.

Dob­meier has a $65 mil­lion A round and a team of 25 to lead for­ward. You may re­call that Dob­meier’s first biotech gig out of Seat­tle Ge­net­ics was with a com­pa­ny called Sil­ver­back. But they ex­pe­ri­enced an ear­ly set­back, says the biotech ex­ec, and he ex­it­ed the com­pa­ny — join­ing Chi­nook back in April.

Ver­sant and Ap­ple Tree were joined by Sam­sara Bio­Cap­i­tal on the launch round.

The Ver­sant team has made a habit of try­ing to get an ear­ly jump on emerg­ing R&D fields. That strat­e­gy, which in­volves cre­at­ing dis­cov­ery teams in some off-beat places like Van­cou­ver, in­clud­ed their re­gen­er­a­tive stem cell play Blue­Rock, which Bay­er just bought out at a uni­corn val­u­a­tion.

They’re fol­low­ing in the foot­steps of com­pa­nies like Goldfinch, a Third Rock start­up in the class of 2016 that re­cent­ly teamed with Gilead on its ap­proach to kid­ney dis­ease. That heav­i­ly back-end­ed deal helped in­spire Ver­sant to go deep­er. An­oth­er com­pa­ny in the field is Rea­ta, which was once al­lied with Ab­b­Vie — ahead of a clin­i­cal im­plo­sion that they’ve been work­ing to re­cov­er from. 

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The slate of products we’re offering here at Endpoints is continuing to grow, and it’s not just limited to editorial. If you haven’t, do visit your reader profile to see if there are any other weekly newsletters you’re interested in — as each comes with its own exclusive content. And don’t miss the publisher’s note from Arsalan Arif on Endpoints Studio, our latest avenue for advertising on Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Usama Malik

Ex-Im­munomedics CFO charged with in­sid­er trad­ing, faces up to 20 years in prison af­ter al­leged­ly tip­ping off girl­friend and rel­a­tives of a PhI­II suc­cess

The former CFO of Immunomedics, who helped steer the company to its $21 billion buyout by Gilead last year, has been charged with insider trading, the Department of Justice announced Thursday.

Usama Malik tipped off his then-girlfriend and four others that a Phase III study for Trodelvy would be stopped early four days before Immunomedics publicly announced the result in April 2020, DoJ alleged in its complaint. The individuals then purchased Immunomedics shares, selling them after the news broke and Immunomedics’ stock price doubled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Merck's new antiviral molnupiravir (Quality Stock Arts / Shutterstock)

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

After South African scientists reported a new Covid-19 variant — dubbed Omicron by the WHO — scientists became concerned about how effective vaccines and monoclonal antibodies might be against it, which has more than 30 mutations in the spike protein.

“I think it is super worrisome,” Dartmouth professor and Adagio co-founder and CEO Tillman Gerngross told Endpoints News this weekend. Moderna CEO Stéphane Bancel echoed similar concerns, telling the Financial Times that experts warned him, “This is not going to be good.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Re­searchers move clos­er to de­ci­pher­ing blood clots from As­traZeneca, J&J's Covid-19 vac­cines

Researchers may be nearing an answer for the mysterious and life-threatening blood clots that appeared on very rare occasions in people who received the J&J or AstraZeneca Covid-19 vaccine.

The new work builds on an early hypothesis researchers in Norway put forward last spring, when the cases first cropped up. They proposed the events were similar to blood clots that can occur in a small subset of patients who receive heparin, one of the most commonly used blood thinners.

Glax­o­SmithK­line, Ox­ford un­veil new part­ner­ship pit­ting buzzy R&D ad­vances against neu­ro­log­i­cal dis­ease

When GlaxoSmithKline trumpeted its return to neuroscience with a $700 million upfront deal with Alector this summer, it touted its early investments in functional genomics as a key guidepost for that deal. Now, the drug giant has partnered up with Oxford to hopefully add jet fuel to its hunt for breakthroughs in the brain.

GSK and Oxford have kickstarted a five-year collaboration aimed at spurring R&D breakthroughs across a range of hard-to-treat diseases like Alzheimer’s and Parkinson’s through the use of genomic testing and machine learning, the partners said Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

In­cor­po­rat­ing Ex­ter­nal Da­ta in­to Clin­i­cal Tri­als: Com­par­ing Dig­i­tal Twins to Ex­ter­nal Con­trol Arms

Most drug development professionals are familiar with the nerve-racking wait for the read-out of a large trial. If it’s negative, is the investigational therapy ineffective? Or could the failure result from an unforeseen flaw in the design or execution of the protocol, rather than a lack of efficacy? The team could spend weeks analyzing data, but a definitive answer may be elusive due to insufficient power for such analyses in the already completed trial. These problems are only made worse if the trial had lower enrollment, or higher dropout than expected due to an unanticipated event like COVID-19. And if a trial is negative, the next one is likely to be larger and more costly — if it happens at all.

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

The safety problems that continue to plague the JAK class as new data highlight some severe side effects are casting a large shadow over AbbVie’s Rinvoq.

As a result of a recent readout highlighting major adverse cardiac events (MACE), malignancy, mortality and thrombosis with Xeljanz a couple of months ago, AbbVie put out a notice late Friday afternoon that it is adding the new class risks to its label for their rival drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select more effective and safer drug candidates in the future.

The combined companies will now serve a wider range of drug research and development scientists, according to Albert Li, who founded IVAL in 2004 and is set to join the Discovery leadership team as the CSO of pharmacology and toxicology.